您现在的位置: 北大分子医学研究所正文

Rui-Ping Xiao

发布时间:2011-01-04   阅读次数:13048  
Rui-Ping Xiao, M.D. Ph.D
Professor
Director of IMM/PKU
Principal Investigator, Laboratory of Signal Transduction
 
Room 322, Ying-Jie Conference Center, Yiheyuan Road 5, Haidian District,
Peking University, Beijing, China 100871
E-mail:  imm@pku.edu.cn
Phone: 86-10-6275-7243
 
Dr. Rui-Ping Xiao was trained as a physician-scientist in both China and the United States. She received her M.D. and medical training at Tong-Ji Medical University, China. In 1988, she went to the United States, and spent 20 years in National Institute on Aging (NIA), NIH, from a postdoctoral fellow to a tenured Senior Investigator and the Chief of the Receptor Signaling Section. Overlapping with her training at NIH, she also completed her Ph.D. study in the Medical School of University of Maryland from 1991 to 1995. Additionally, in 2005, she was invited by Peking University to serve as the Founding Director of the Institute of Molecular of Medicine (IMM) at Peking University (initially as a volunteer), and became a full-time returnee through the Chinese 1000-elite Program in 2010.
 
Over the past decade, Dr. Xiao has been serving as the Founding Director of the IMM-PKU. As the first autonomous research institute, the IMM-PKU  was founded in January 2005, and was designed as a interdisciplinary research center reflecting of PKU’s focus on excellence in biomedical research and education. Dr. Xiao’s research has been focused on cardiovascular and metabolic diseases, with a major emphasis on a translational approach to take bench discoveries into clinically relevant situations. Ongoing research directions include signaling pathways involved in metabolic syndrome and associated cardiovascular complications.
 
Currently, Dr. Xiao serves as a Council Member of the International Society of Heart Research and an Associate Editor of the New England Journal of Medicine and an Editorial Board Member of multiple international top journals.
Selected Publications since 2000:
    1. 1. Zhang, T., Zhang, Y., Cui, M., Jin, L., Wang, Y., Lv, F., Liu, Y., Zheng, W., Shang, H., Zhang, J., Zhang, M., Wu, H.K., Guo, J., Zhang, X., Hu, X., Cao, C.M., Xiao, R.P.: CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 22:175-182, 2016.
      2. Zhu, W., Tsang, S., Browe, D.M., Woo, A.Y., Huang, Y., Xu, C., Liu, J.F., Lv, F., Zhang, Y., Xiao, R.P.: Interaction of β1-Adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling. JCI Insight (创刊号). 2016 (In press).
      3. Chandramouli, C., Varma, U., Stevens, E.M., Xiao, R.P., Stapleton, D.I., Mellor, K.M., Delbridge, L.M.: Myocardial glycogen dynamics - new perspectives on disease mechanisms. Clin Exp Pharmacol Physiol. 42:415-425, 2015.
      4. Liu, F., Song, R., Feng, Y., Guo, J., Chen, Y., Zhang, Y., Chen, T., Wang, Y., Huang, Y., Li, C.Y., Cao, C., Zhang, Y., Hu, X., Xiao, R.P.: Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α. Circulation. 131:795-804, 2015.
      5. Guo, J., Xie, N., Li, G., Zhang, Y., Lv, F., Guo, S., Feng, Y., Cao, C.M., Xiao, R.P.: p55γ functional mimetic peptide N24 blocks vascular proliferative disorders. J Mol Med (Berl). 93:1107-1118, 2015
      6. Li, G., Xie, N., Yao, Y., Zhang, Y., Guo, J., Feng, Y., Lv, F., Xiao, R.P., Cao, C.M.: Identification of PI3K regulatory subunit p55γ as a novel inhibitor of vascular smooth muscle cell proliferation and neointimal formation. Cardiovasc Res. 105:75-85, 2015.
      7. Woo, A.Y., Song, Y., Zhu, W., Xiao, R.P.: Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor. Br J Pharmacol. 172:5477-5488, 2014.
      8.Woo, A.Y., Song, Y., Xiao, R.P., Zhu, W.: Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol. 172:5444-5456, 2014.
      9.Woo, A.Y., Jozwiak, K., Toll, L., Tanga, M.J., Kozocas, J.A., Jimenez, L., Huang, Y., Song, Y., Plazinska, A., Pajak, K., Paul, R.K., Bernier, M., Wainer, I.W., Xiao, R.P.: Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor. J Biol Chem. 289:19351-19363, 2014.
      10.Song, R., Peng, W., Zhang, Y., Lv, F., Wu, H.K., Guo, J., Cao, Y., Pi, Y., Zhang, X., Jin, L., Zhang, M., Jiang, P., Liu, F., Meng, S., Zhang, X., Jiang, P., Cao, C.M., Xiao, R.P.: Central role of ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature, 494: 375-379, 2013.
      11.Tae, H.J., Kim, J.M., Park, S., Tomiya, N., Li, G., Wei, W., Petrashevskaya, N., Ahmet, I., Pang, J., Cruschwitz, S., Riebe, R.A., Zhang, Y., Morrell, C.H., Browe, D., Lee, Y.C., Xiao R.P., Talan, M.I., Lakatta, E.G., Lin, L.: The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med, 91:1369-1381, 2013.
      12.Xiao, R.P.: Bioimaging for cardiometabolic translational medicine: from cellular messengers to organism function. J Mol Med, 91: 905-906, 2013.
      13.Whelan, R.S., Konstantinidis, K., Xiao, R.P., Kitsis, R.N.: Cardiomyocyte life-death decisions in response to chronic β-adrenergic signaling. Circ Res, 112: 408-410, 2013.
      14.Liu, W., Zi, M., Tsui, H., Chowdhury, S.K., Zeef, L., Meng, Q.J., Travis, M., Prehar, S., Berry, A., Hanley, N., Neyses, L., Xiao, R.P., Oceandy, D., Ke, Y., Solaro, R.J., Cartwright, E.J., Lei, M., Wang, X.: A novel immunomodulator, FTY-720, reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT signaling and periostin. Circ Heart Fail, 6: 833-844, 2013.
      15.Zhu, W., Petrashevskaya, N., Ren, S., Zhao, A., Chakir, K., Gao, E., Chuprun, J.K., Wang, Y., Talan, M., Dorn, G.W. 2nd., Lakatta, E.G., Koch, W.J., Feldman, A.M., Xiao, R.P.: Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res. 110: 265-74, 2012.
      16.Weisleder, N., Takizawa, N., Lin, P., Wang, X., Cao, C.M., Zhang, Y., Tan, T., Ferrante, C., Zhu, H., Chen, P.J., Yan, R., Sterling, M., Zhao, X., Hwang, M., Cai, C., Cheng, H., Takeshima, H., Xiao, R.P., Ma, J.: Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 4: 139ra85, 2012.
      17.Xu, H.E., Xiao, R.P.: A new era for GPCR research: structures, biology and drug discovery. Acta Pharmacol Sin. 33: 289-290, 2012.
      18.Zhang, Y., Zhang, T., Cao, C.M., Xiao, R.P.: mTOR: good, bad, or ugly? Cardiovasc Res. 95: 261-262, 2012.
      19.Lin, P., Zhu, H., Cai, C., Wan, X., Cao, C.M., Xiao, R.P., Pan, Z., Weisleder, N., Takeshima, H., Ma, J.: Non-muscle myosin IIA facilitates vesicle trafficking for MG53-mediated cell membrane repair. FASEB J. 26: 1875-83, 2012.
      20.Woo, A.Y., Xiao R.P.: β-adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin. 33: 335-341, 2012.
      21.Talan, M.I., Ahmet, I., Xiao, R.P., Lakatta, E.G.: β2AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol. 51: 529-33, 2011.
      22.Liu, W., Zi. M., Naumann, R., Ulm, S., Jin, J., Taglieri, D.M., Prehar, S., Gui, J., Tsui, H., Xiao, R.P., Neyses, L., Solaro, R.J., Ke, Y., Cartwright, E.J., Lei, M., Wang, X.: Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation. 124: 2702-2715, 2011.
      23.Toll, L., Jimenez, L., Waleh, N., Jozwiak, K., Woo, A.Y., Xiao, R.P., Bernier. M., Wainer. I.W.: β2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther. 336: 524-32, 2011.
      24.Chakir, K., Zhu, W., Tsang. S., Woo, A.Y., Yang, D., Wang, X., Zeng, X., Rhee, M.H., Mende, U., Koitabashi, N., Takimoto, E., Blumer, K.J., Lakatta, E.G., Kass, D.A., Xiao, R.P.: RGS2 is a primary terminator of β2-adrenergic receptor-mediated Gi signaling. J Mol Cell Cardiol. 50: 1000-7, 2011.
      25.Jozwiak, K., Plazinska, A., Toll, L., Jimenez, L., Woo, A.Y., Xiao, R.P., Wainer, I.W.: Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition. Chirality. 23 Suppl 1:E1-6. doi: 10.1002/chir.20963, 2011.
      26.Chakir, K., Depry, C., Dimaano, V.L., Zhu, W.Z., Vanderheyden, M., Bartunek, J., Abraham, T.P., Tomaselli, G.F., Liu, S.B., Xiang, Y.K., Zhang, M., Takimoto, E., Dulin, N., Xiao, R.P., Zhang, J., Kass, D.A.: Gs-biased β2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med. 3: 100ra88, 2011.
      27.Zhu, W., Woo, A.Y., Zhang, Y., Cao, C.M., Xiao, R.P.: β-adrenergic receptor subtype signaling in the heart: from bench to the bedside. Curr Top Membr. 67: 191-204. 2011.
      28.Zhang, Y., Lv, F.X., Jin, L., Peng, W., Song, R.S., Ma, J., Cao, C.M., Xiao, R.P.: MG53 Participates in ischemic postconditioning through the RISK signaling pathway. Cardiovasc Res. 91: 108-115, 2011.
      29.Ekhterae, D., Hinmon, R., Zeeshan, A., Parish, L., Zhu W., Xiao, R.P., Gorman, R.C., Gorman, J.H.: Infarction induced myocardial apoptosis and ARC activation. J Surg Res. 166: 59-67, 2011.
      30.Wang, X., Xie, W., Zhang, Y., Lin, P., Han, L., Han, P., Wang, Y., Chen, Z., Ji, G., Zheng, M., Weisleder, N., Xiao, R.P., Takeshima, H., Ma. J, Cheng, H.: Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res. 107: 76-83, 2010.
      31.Cao, C.M., Zhang, Y., Weislede, N., Ferrante, C., Wang, X.H., Lv, F., Zhang, Y., Song, R.S., Hwang, M., Jin, L., Guo, J., Peng, W., Li, G., Nishi, M., Takeshima, H., Ma, J., Xiao, R.P.: MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 121: 2565-74, 2010.
      32.Zheng, M., Xiao, R.P.: Role of mitofusin-2 in cardiovascular oxidative stress. J Mol Med. 88: 987-991, 2010.
      33.Zhang, Y., Cao, C.M., Xiao, R.P.: Kinase activity-independent anchoring function of protein kinase C. Am J Physiol Cell Physiol. 299: C733-735, 2010.
      34.Jozwiak, K., Toll, L., Jimenez, L., Woo, A.Y., Xiao, R.P., Wainer, I.W.: The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the 2-adrenoceptor. Biochem Pharmacol. 79: 1610-5, 2010.
      35.Jozwiak, K., Woo, A.Y.H., Tanga, M.J., Toll, L., Jimenez, L., Kozocas, J.A., Plazinska, A., Xiao, R.P., Wainer, I.W.: Comparative molecular field analysis of fenoterol derivatives: a platform towards highly selective and effective β2-adrenergic receptor agonists. Bioorganic & Medicinal Chemistry. 18: 728-36, 2010.
      36.Li, Q., Li, G., Lan, X., Zheng, M., Chen, K.H., Cao, C., Xiao, R.P.: Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of PI3K-Akt axis. J Biol Chem. 285: 9535-44, 2010.
      37.Tsang, S., Woo, A.Y.H., Zhu, W., Xiao, R.P.: Deregulation of RGS2 in cardiovascular diseases. Frontiers in Bioscience. 2: 547-57, 2010.
      38.Peng, W., Zhang, Y., Zheng, M., Cheng, H., Zhu, W., Cao, C.M., Xiao, R.P: Cardioprotection by CaMKII-δB is mediated by phosphorylation of HSF1 and subsequent expression of inducible HSP70. Circ Res. 106: 102-10, 2010.
关闭